|
FR901228A
(fr)
|
1943-01-16 |
1945-07-20 |
Deutsche Edelstahlwerke Ag |
Système d'aimant à entrefer annulaire
|
|
US2940972A
(en)
|
1957-06-27 |
1960-06-14 |
Thomae Gmbh Dr K |
Tri-and tetra-substituted pteridine derivatives
|
|
US4666828A
(en)
|
1984-08-15 |
1987-05-19 |
The General Hospital Corporation |
Test for Huntington's disease
|
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
|
US4801531A
(en)
|
1985-04-17 |
1989-01-31 |
Biotechnology Research Partners, Ltd. |
Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
|
|
US5272057A
(en)
|
1988-10-14 |
1993-12-21 |
Georgetown University |
Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
|
|
US5192659A
(en)
|
1989-08-25 |
1993-03-09 |
Genetype Ag |
Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
|
|
US5710158A
(en)
|
1991-05-10 |
1998-01-20 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
|
|
GB9125001D0
(en)
|
1991-11-25 |
1992-01-22 |
Ici Plc |
Heterocyclic compounds
|
|
AU661533B2
(en)
|
1992-01-20 |
1995-07-27 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
EP0698015A1
(en)
|
1993-05-14 |
1996-02-28 |
Genentech, Inc. |
Preparation of n-cyanodithioimino-carbonates and 3-mercapto-5-amino-1h-1,2,4-triazole
|
|
US5700823A
(en)
|
1994-01-07 |
1997-12-23 |
Sugen, Inc. |
Treatment of platelet derived growth factor related disorders such as cancers
|
|
IL115256A0
(en)
|
1994-11-14 |
1995-12-31 |
Warner Lambert Co |
6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
|
|
US6331555B1
(en)
|
1995-06-01 |
2001-12-18 |
University Of California |
Treatment of platelet derived growth factor related disorders such as cancers
|
|
WO1998004689A1
(en)
|
1995-07-31 |
1998-02-05 |
Urocor, Inc. |
Biomarkers and targets for diagnosis, prognosis and management of prostate disease
|
|
US6218529B1
(en)
|
1995-07-31 |
2001-04-17 |
Urocor, Inc. |
Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
|
|
JP4130700B2
(ja)
|
1996-02-26 |
2008-08-06 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
抗腫瘍剤含有組成物
|
|
TW472045B
(en)
|
1996-09-25 |
2002-01-11 |
Astra Ab |
Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation
|
|
JP2002500675A
(ja)
|
1997-05-28 |
2002-01-08 |
アヴェンティス ファーマシューティカルズ プロダクツ インコーポレイテッド |
血小板由来成長因子及び／又はｐ５６▲上ｌｃｋ▼チロシンキナーゼを阻害するキノリン及びキノキサリン化合物
|
|
US6235740B1
(en)
|
1997-08-25 |
2001-05-22 |
Bristol-Myers Squibb Co. |
Imidazoquinoxaline protein tyrosine kinase inhibitors
|
|
UA71555C2
(en)
|
1997-10-06 |
2004-12-15 |
Zentaris Gmbh |
Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
|
|
AU1918299A
(en)
|
1998-02-23 |
1999-09-06 |
Warner-Lambert Company |
Substituted quinoxaline derivatives as interleukin-8 receptor antagonists
|
|
WO2000042026A1
(en)
|
1999-01-15 |
2000-07-20 |
Novo Nordisk A/S |
Non-peptide glp-1 agonists
|
|
US7135311B1
(en)
|
1999-05-05 |
2006-11-14 |
Institut Curie |
Means for detecting and treating pathologies linked to FGFR3
|
|
CA2372990C
(en)
|
1999-05-05 |
2007-06-19 |
Institut Curie |
Means for detecting and treating pathologies linked to fgfr3
|
|
NZ516872A
(en)
|
1999-09-15 |
2003-10-31 |
Warner Lambert Co |
Pteridinones as kinase inhibitors
|
|
DE10013318A1
(de)
|
2000-03-17 |
2001-09-20 |
Merck Patent Gmbh |
Formulierung enthaltend Chinoxalinderivate
|
|
WO2002076985A1
(en)
|
2001-03-23 |
2002-10-03 |
Smithkline Beecham Corporation |
Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
|
|
US20030235628A1
(en)
|
2001-09-19 |
2003-12-25 |
Rajneesh Taneja |
Methods and pharmaceutical formulations for protecting pharmaceutical compounds from acidic environments
|
|
DE60223720T2
(de)
|
2001-12-18 |
2008-10-30 |
Merck & Co., Inc. |
Heteroaryl-substituierte pyrazol-modulatoren des metabotropen glutamatrezeptors-5
|
|
US20030229067A1
(en)
|
2001-12-20 |
2003-12-11 |
Arlindo Castelhano |
Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use
|
|
UA82058C2
(uk)
|
2001-12-24 |
2008-03-11 |
Астразенека Аб |
Заміщені похідні хіназоліну як інгібітори ауроракінази, спосіб їх одержання, фармацевтична композиція на їх основі
|
|
JP2003213463A
(ja)
|
2002-01-17 |
2003-07-30 |
Sumitomo Chem Co Ltd |
金属腐食防止剤および洗浄液
|
|
AU2003223467B2
(en)
|
2002-04-08 |
2007-10-04 |
Merck Sharp & Dohme Corp. |
Inhibitors of Akt activity
|
|
US7265378B2
(en)
|
2002-07-10 |
2007-09-04 |
E. I. Du Pont De Nemours And Company |
Electronic devices made with electron transport and/or anti-quenching layers
|
|
US7196090B2
(en)
|
2002-07-25 |
2007-03-27 |
Warner-Lambert Company |
Kinase inhibitors
|
|
US7825132B2
(en)
|
2002-08-23 |
2010-11-02 |
Novartis Vaccines And Diagnostics, Inc. |
Inhibition of FGFR3 and treatment of multiple myeloma
|
|
CA2500727A1
(en)
|
2002-10-03 |
2004-04-15 |
Targegen, Inc. |
Vasculostatic agents and methods of use thereof
|
|
AU2003301654A1
(en)
|
2002-10-22 |
2004-05-13 |
Dainippon Pharmaceutical Co., Ltd. |
Stabilized composition
|
|
AR043059A1
(es)
|
2002-11-12 |
2005-07-13 |
Bayer Pharmaceuticals Corp |
Derivados de indolil pirazinona utiles para el tratamiento de trastornos hiper-proliferativos
|
|
US7098332B2
(en)
|
2002-12-20 |
2006-08-29 |
Hoffmann-La Roche Inc. |
5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
|
|
JP2006516561A
(ja)
|
2003-01-17 |
2006-07-06 |
ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー |
細胞増殖の阻害剤としての２−アミノピリジン置換ヘテロ環類
|
|
US20040204450A1
(en)
|
2003-03-28 |
2004-10-14 |
Pfizer Inc |
Quinoline and quinoxaline compounds
|
|
WO2004098494A2
(en)
|
2003-04-30 |
2004-11-18 |
Cytokinetics, Inc. |
Compounds, compositions, and methods
|
|
MXPA05012281A
(es)
|
2003-05-14 |
2006-05-19 |
Torreypines Therapeutics Inc |
Compuestos y uso de los mismos en la modulacion beta amiloide.
|
|
WO2004104003A1
(de)
|
2003-05-23 |
2004-12-02 |
Zentaris Gmbh |
Neue pyridopyrazine und deren verwendung als modulatoren von kinasen
|
|
DE10323345A1
(de)
|
2003-05-23 |
2004-12-16 |
Zentaris Gmbh |
Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren
|
|
WO2005007099A2
(en)
|
2003-07-10 |
2005-01-27 |
Imclone Systems Incorporated |
Pkb inhibitors as anti-tumor agents
|
|
CA2533417A1
(en)
|
2003-07-21 |
2005-02-03 |
Mitchell A. Avery |
Design and synthesis of optimized ligands for ppar
|
|
ZA200600424B
(en)
|
2003-08-01 |
2007-05-30 |
Genelabs Tech Inc |
Bicyclic imidazol derivatives against flaviviridae
|
|
WO2005039587A1
(en)
|
2003-10-17 |
2005-05-06 |
4 Aza Bioscience Nv |
Heterocycle-substituted pteridine derivatives and their use in therapy
|
|
US20060188568A1
(en)
|
2003-10-30 |
2006-08-24 |
Lupin Limited |
Stable formulations of ace inhibitors and methods for preparation thereof
|
|
KR101224410B1
(ko)
|
2003-11-07 |
2013-01-23 |
노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 |
퀴놀리논 화합물을 합성하는 방법
|
|
EA009875B1
(ru)
|
2003-11-20 |
2008-04-28 |
Янссен Фармацевтика Н.В. |
6-алкенил и 6-фенилалкил замещенные 2-хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(адф-рибоза) полимеразы
|
|
MXPA06005735A
(es)
|
2003-11-24 |
2006-08-17 |
Hoffmann La Roche |
Pirazolil e imidazolil pirimidinas.
|
|
HRP20100675T1
(hr)
|
2003-12-23 |
2011-01-31 |
Astex Therapeutics Limited |
Derivati pirazola kao modulatori protein kinaze
|
|
US7205316B2
(en)
|
2004-05-12 |
2007-04-17 |
Abbott Laboratories |
Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands
|
|
US7098222B2
(en)
|
2004-05-12 |
2006-08-29 |
Abbott Laboratories |
Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
|
|
US7446196B2
(en)
|
2004-06-03 |
2008-11-04 |
Kosan Biosciences, Incorporated |
Leptomycin compounds
|
|
AU2005278959A1
(en)
|
2004-08-31 |
2006-03-09 |
Astrazeneca Ab |
Quinazolinone derivatives and their use as B-Raf inhibitors
|
|
WO2006040052A1
(en)
|
2004-10-14 |
2006-04-20 |
F. Hoffmann-La Roche Ag |
1,5-naphthyridine azolidinones having cdk1 antiproliferative activity
|
|
WO2006040568A1
(en)
|
2004-10-15 |
2006-04-20 |
Astrazeneca Ab |
Quinoxalines as b raf inhibitors
|
|
EP1659175A1
(en)
|
2004-11-18 |
2006-05-24 |
Institut Curie |
Alterations in seborrheic keratoses and their applications
|
|
MX2007007038A
(es)
|
2004-12-09 |
2008-03-07 |
Insys Therapeutics Inc |
Formulacion de dronabinol en temperatura ambiente.
|
|
EP2650011A1
(en)
|
2004-12-24 |
2013-10-16 |
Spinifex Pharmaceuticals Pty Ltd |
Method of treatment or prophylaxis
|
|
MX2007008141A
(es)
|
2005-01-03 |
2007-12-10 |
Lupin Ltd |
Composicion farmaceutica de sustancias labiles en medio acido.
|
|
EP1848704A4
(en)
|
2005-02-14 |
2011-05-11 |
Bionomics Ltd |
Novel tubulin polymerisation inhibitors
|
|
EP1853261B1
(de)
|
2005-03-03 |
2017-01-11 |
Universität des Saarlandes |
Selektive hemmstoffe humaner corticoidsynthasen
|
|
JP2008540535A
(ja)
|
2005-05-12 |
2008-11-20 |
メルク エンド カムパニー インコーポレーテッド |
チロシンキナーゼ阻害剤
|
|
CA2606598C
(en)
|
2005-05-13 |
2014-12-23 |
Topotarget Uk Limited |
Pharmaceutical formulations of hdac inhibitors
|
|
AU2006247315A1
(en)
|
2005-05-18 |
2006-11-23 |
Wyeth |
4, 6-diamino-[1,7] naphthyridine-3-carbonitrile inhibitors of Tpl2 kinase and methods of making and using the same
|
|
WO2006132363A1
(ja)
|
2005-06-10 |
2006-12-14 |
Chugai Seiyaku Kabushiki Kaisha |
メグルミンを含有するタンパク質製剤の安定化剤、およびその利用
|
|
GB0513692D0
(en)
|
2005-07-04 |
2005-08-10 |
Karobio Ab |
Novel pharmaceutical compositions
|
|
UA100358C2
(xx)
|
2005-08-26 |
2012-12-25 |
Мерк Сероно Са |
Похідні піразину та їх застосування
|
|
EP2364974A1
(en)
|
2005-10-07 |
2011-09-14 |
Exelixis, Inc. |
N-(3-Phenylamino-quinoxalin-2-yl)-benzenesulfonamide derivatives as phosphatidylinositol 3-kinase inhibitors
|
|
KR101400905B1
(ko)
|
2005-11-11 |
2014-05-29 |
아에테르나 젠타리스 게엠베하 |
신규한 피리도피라진 및 키나제의 조절제로서의 이의 용도
|
|
US8217042B2
(en)
|
2005-11-11 |
2012-07-10 |
Zentaris Gmbh |
Pyridopyrazines and their use as modulators of kinases
|
|
EP1790342A1
(de)
|
2005-11-11 |
2007-05-30 |
Zentaris GmbH |
Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege
|
|
CN1966500B
(zh)
|
2005-11-17 |
2011-03-30 |
中国科学院上海药物研究所 |
一类喹喔啉类衍生物、制法及用途
|
|
WO2007061127A1
(ja)
|
2005-11-22 |
2007-05-31 |
Eisai R & D Management Co., Ltd. |
多発性骨髄腫に対する抗腫瘍剤
|
|
ME02736B
(me)
*
|
2005-12-21 |
2017-10-20 |
Janssen Pharmaceutica Nv |
Triazolopiridazini kao modulatori tirozin kinaze
|
|
TW200808739A
(en)
|
2006-04-06 |
2008-02-16 |
Novartis Vaccines & Diagnostic |
Quinazolines for PDK1 inhibition
|
|
JP2009535393A
(ja)
|
2006-05-01 |
2009-10-01 |
ファイザー・プロダクツ・インク |
置換２−アミノ縮合複素環式化合物
|
|
GB0609621D0
(en)
|
2006-05-16 |
2006-06-21 |
Astrazeneca Ab |
Novel co-crystal
|
|
WO2007135027A1
(de)
|
2006-05-24 |
2007-11-29 |
Boehringer Ingelheim International Gmbh |
Substituierte pteridine, die mit einem viergliedrigen heterocyclus substituiert sind
|
|
JO3235B1
(ar)
|
2006-05-26 |
2018-03-08 |
Astex Therapeutics Ltd |
مركبات بيررولوبيريميدين و استعمالاتها
|
|
CA2657702A1
(en)
|
2006-07-03 |
2008-01-10 |
Vereniging Voor Christelijk Hoger Onderwijs Wetenschappelijk Onderzoek E N Patieentenzorg |
Quinazolines and related heterocyclic comp0unds, and their therapeutic use
|
|
JP2010500994A
(ja)
|
2006-08-16 |
2010-01-14 |
エグゼリクシス， インコーポレイテッド |
Ｐｉ３ｋおよびｍｅｋモジュレーターを使用する方法
|
|
US8148361B2
(en)
|
2006-11-10 |
2012-04-03 |
Bristol-Myers Squibb Company |
Kinase inhibitors
|
|
JP2008127446A
(ja)
|
2006-11-20 |
2008-06-05 |
Canon Inc |
１，５−ナフチリジン化合物及び有機発光素子
|
|
BRPI0719333A2
(pt)
|
2006-11-22 |
2014-02-04 |
Incyte Corp |
Midazotriazinas e imidazopirimidinas como inbidores de cinase
|
|
JP2010513278A
(ja)
|
2006-12-13 |
2010-04-30 |
シェーリング コーポレイション |
Ｉｇｆ１ｒインヒビターを用いた癌の処置方法
|
|
JP2010514695A
(ja)
|
2006-12-21 |
2010-05-06 |
プレキシコン，インコーポレーテッド |
キナーゼ調節のための化合物および方法およびそのための適応症
|
|
KR20090092287A
(ko)
|
2006-12-22 |
2009-08-31 |
노파르티스 아게 |
Ｐｄｋ１ 억제를 위한 퀴나졸린
|
|
HRP20150642T1
(hr)
|
2006-12-22 |
2015-08-14 |
Astex Therapeutics Limited |
BICIKLIÄŚKE HETEROCIKLIÄŚKE TVARI KAO INHIBITORI FGFR-a
|
|
KR20080062876A
(ko)
|
2006-12-29 |
2008-07-03 |
주식회사 대웅제약 |
신규한 항진균성 트리아졸 유도체
|
|
WO2008109369A2
(en)
|
2007-03-02 |
2008-09-12 |
Mdrna, Inc. |
Nucleic acid compounds for inhibiting tnf gene expression and uses thereof
|
|
US8163923B2
(en)
|
2007-03-14 |
2012-04-24 |
Advenchen Laboratories, Llc |
Spiro substituted compounds as angiogenesis inhibitors
|
|
EP2150255A4
(en)
|
2007-05-10 |
2011-10-05 |
Glaxosmithkline Llc |
CHINOXALINE DERIVATIVES AS P13 KINASE INHIBITORS
|
|
EP1990342A1
(en)
|
2007-05-10 |
2008-11-12 |
AEterna Zentaris GmbH |
Pyridopyrazine Derivatives, Process of Manufacturing and Uses thereof
|
|
WO2008150827A1
(en)
|
2007-05-29 |
2008-12-11 |
Smithkline Beecham Corporation |
Naphthyridine, derivatives as p13 kinase inhibitors
|
|
AR066879A1
(es)
|
2007-06-08 |
2009-09-16 |
Novartis Ag |
Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
|
|
KR101251933B1
(ko)
|
2007-06-20 |
2013-04-09 |
미쓰비시 타나베 파마 코퍼레이션 |
신규한 말론산술폰아미드 유도체 및 그 의약 용도
|
|
EP2170894A1
(en)
*
|
2007-06-21 |
2010-04-07 |
Janssen Pharmaceutica N.V. |
Polymorphic and hydrate forms, salts and process for preparing 6-{difluoro[6-(1-methyl-1h-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}quinoline
|
|
JP2010532758A
(ja)
|
2007-07-06 |
2010-10-14 |
オーエスアイ・ファーマスーティカルズ・インコーポレーテッド |
組み合わせ抗癌療法
|
|
WO2009020990A1
(en)
|
2007-08-08 |
2009-02-12 |
Smithkline Beecham Corporation |
2- [ (2-{phenylamino}-1h-pyrrolo [2, 3-d] pyrimidin-4-yl) amino] benzamide derivatives as igf-1r inhibitors for the treatment of cancer
|
|
WO2009019518A1
(en)
|
2007-08-09 |
2009-02-12 |
Astrazeneca Ab |
Pyrimidine compounds having a fgfr inhibitory effect
|
|
WO2009021083A1
(en)
|
2007-08-09 |
2009-02-12 |
Smithkline Beecham Corporation |
Quinoxaline derivatives as pi3 kinase inhibitors
|
|
WO2013173485A1
(en)
|
2012-05-15 |
2013-11-21 |
Predictive Biosciences, Inc. |
Detection of bladder cancers
|
|
US20090054304A1
(en)
|
2007-08-23 |
2009-02-26 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5 for treatment of disease
|
|
JP5480813B2
(ja)
|
2007-11-16 |
2014-04-23 |
インサイト・コーポレイション |
Ｊａｎｕｓキナーゼ阻害剤としての置換複素環
|
|
AU2008340429C1
(en)
|
2007-12-21 |
2016-09-08 |
F. Hoffmann-La Roche Ag |
Antibody formulation
|
|
US20110129456A1
(en)
|
2008-05-05 |
2011-06-02 |
Yaolin Wang |
Sequential Administration of Chemotherapeutic Agents for Treatment of Cancer
|
|
KR101257158B1
(ko)
|
2008-05-23 |
2013-04-23 |
노파르티스 아게 |
단백질 티로신 키나제 억제제로서의 퀴놀린 및 퀴녹살린의 유도체
|
|
MY161597A
(en)
|
2008-11-15 |
2017-04-28 |
Rib-X Pharmaceuticals Inc |
Antimicrobial compositions
|
|
US8592448B2
(en)
|
2008-11-20 |
2013-11-26 |
OSI Pharmaceuticals, LLC |
Substituted pyrrolo[2,3-b]-pyridines and -pyrazines
|
|
CN102361863B
(zh)
|
2009-01-21 |
2014-12-03 |
巴斯利尔药物股份公司 |
新的二环抗生素
|
|
EP2391623A4
(en)
|
2009-02-02 |
2012-09-05 |
Merck Sharp & Dohme |
HAMMER OF ACT ACTIVITY
|
|
TW201041888A
(en)
|
2009-05-06 |
2010-12-01 |
Plexxikon Inc |
Compounds and methods for kinase modulation, and indications therefor
|
|
FR2945950A1
(fr)
|
2009-05-27 |
2010-12-03 |
Elan Pharma Int Ltd |
Compositions de nanoparticules anticancereuses et procedes pour les preparer
|
|
KR20120051643A
(ko)
|
2009-06-12 |
2012-05-22 |
쏘시에떼 스플리코 |
조기 노화, 구체적으로 조로증을 치료하는데 유용한 화합물
|
|
EA201200260A1
(ru)
|
2009-08-12 |
2012-09-28 |
Новартис Аг |
Гетероциклические гидразоны и их применение для лечения рака и воспаления
|
|
MX2012002274A
(es)
|
2009-09-03 |
2012-09-07 |
Bioenergenix |
Compuestos heterociclicos para la inhibicion de pask.
|
|
US9340528B2
(en)
|
2009-09-04 |
2016-05-17 |
Bayer Pharma Aktiengesellschaft |
Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
|
|
CN104666272A
(zh)
|
2009-09-18 |
2015-06-03 |
赛诺菲 |
稳定性提高的(z)-2-氰基-3-羟基-丁-2-烯酸-(4’-三氟甲基苯基)-酰胺片剂制剂
|
|
US20110123545A1
(en)
|
2009-11-24 |
2011-05-26 |
Bristol-Myers Squibb Company |
Combination of vegfr2 and igf1r inhibitors for the treatment of proliferative diseases
|
|
EP2332939A1
(en)
|
2009-11-26 |
2011-06-15 |
Æterna Zentaris GmbH |
Novel Naphthyridine derivatives and the use thereof as kinase inhibitors
|
|
RU2639876C2
(ru)
|
2010-03-30 |
2017-12-25 |
Версеон Корпорейшн |
Мультизамещенные ароматические соединения в качестве ингибиторов тромбина
|
|
GB201007286D0
(en)
|
2010-04-30 |
2010-06-16 |
Astex Therapeutics Ltd |
New compounds
|
|
US8513421B2
(en)
|
2010-05-19 |
2013-08-20 |
Millennium Pharmaceuticals, Inc. |
Substituted hydroxamic acids and uses thereof
|
|
JP5894980B2
(ja)
|
2010-05-24 |
2016-03-30 |
インテリカイン， エルエルシー |
複素環式化合物およびその使用
|
|
GB201020179D0
(en)
|
2010-11-29 |
2011-01-12 |
Astex Therapeutics Ltd |
New compounds
|
|
CN102532141A
(zh)
*
|
2010-12-08 |
2012-07-04 |
中国科学院上海药物研究所 |
[1，2，4]三唑并[4，3-b][1，2，4]三嗪类化合物、其制备方法和用途
|
|
US8987257B2
(en)
|
2011-01-31 |
2015-03-24 |
Novartis Ag |
Heterocyclic derivatives
|
|
JP2014510265A
(ja)
|
2011-02-02 |
2014-04-24 |
アムジェン インコーポレイテッド |
Ｉｇｆ−１ｒの阻害に関する方法および組成物
|
|
EP2678018A4
(en)
|
2011-02-23 |
2015-09-30 |
Intellikine Llc |
COMBINATION OF CHINESE HEMMER AND USES THEREOF
|
|
WO2012118492A1
(en)
|
2011-03-01 |
2012-09-07 |
Array Biopharma Inc. |
Heterocyclic sulfonamides as raf inhibitors
|
|
JP2014519813A
(ja)
|
2011-04-25 |
2014-08-21 |
オーエスアイ・ファーマシューティカルズ，エルエルシー |
癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用
|
|
JP6002223B2
(ja)
|
2011-08-26 |
2016-10-05 |
ニューファーマ， インコーポレイテッド |
特定の化学的実体、組成物、および方法
|
|
US9518029B2
(en)
|
2011-09-14 |
2016-12-13 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
|
EP2757885B1
(en)
|
2011-09-21 |
2017-03-15 |
Neupharma, Inc. |
Certain chemical entites, compositions, and methods
|
|
EP2761300A4
(en)
|
2011-09-27 |
2015-12-02 |
Univ Michigan |
Recurrent genital fusion in breast cancer
|
|
JP2014528451A
(ja)
|
2011-10-04 |
2014-10-27 |
ギリアード カリストガ エルエルシー |
Ｐｉ３ｋの新規キノキサリン阻害剤
|
|
GB201118656D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
|
KR20140090218A
(ko)
|
2011-10-28 |
2014-07-16 |
노파르티스 아게 |
신규 퓨린 유도체 및 질환의 치료에서의 그의 용도
|
|
GB201118654D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
|
JO3210B1
(ar)
|
2011-10-28 |
2018-03-08 |
Merck Sharp & Dohme |
مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة
|
|
GB201118652D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
|
GB201118675D0
(en)
|
2011-10-28 |
2011-12-14 |
Astex Therapeutics Ltd |
New compounds
|
|
AR088941A1
(es)
|
2011-11-23 |
2014-07-16 |
Bayer Ip Gmbh |
Anticuerpos anti-fgfr2 y sus usos
|
|
WO2013088191A1
(en)
|
2011-12-12 |
2013-06-20 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3
|
|
CN104379740B
(zh)
|
2012-03-08 |
2019-05-14 |
安斯泰来制药株式会社 |
新型fgfr3融合体
|
|
WO2013151913A1
(en)
|
2012-04-03 |
2013-10-10 |
Novartis Ag |
Tyrosine kinase inhibitor combinations and their use
|
|
US9254288B2
(en)
|
2012-05-07 |
2016-02-09 |
The Translational Genomics Research Institute |
Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof
|
|
GB201209609D0
(en)
|
2012-05-30 |
2012-07-11 |
Astex Therapeutics Ltd |
New compounds
|
|
GB201209613D0
(en)
|
2012-05-30 |
2012-07-11 |
Astex Therapeutics Ltd |
New compounds
|
|
WO2014007369A1
(ja)
|
2012-07-05 |
2014-01-09 |
独立行政法人国立がん研究センター |
Ｆｇｆｒ２融合遺伝子
|
|
WO2014011672A1
(en)
|
2012-07-09 |
2014-01-16 |
Coherus Biosciences, Inc. |
Etanercept formulations exhibiting marked reduction in sub-visible particles
|
|
US20150203589A1
(en)
|
2012-07-24 |
2015-07-23 |
The Trustees Of Columbia University In The City Of New York |
Fusion proteins and methods thereof
|
|
ES2932954T5
(en)
|
2012-07-24 |
2025-10-28 |
Univ Columbia |
Fgfr-tacc fusion proteins and methods thereof
|
|
RU2015102194A
(ru)
|
2012-07-27 |
2016-09-20 |
Дженентек, Инк. |
Способы лечения связанных с fgfr3 состояний
|
|
KR101942148B1
(ko)
|
2012-09-27 |
2019-01-24 |
추가이 세이야쿠 가부시키가이샤 |
Ｆｇｆｒ３ 융합 유전자 및 그것을 표적으로 하는 의약
|
|
AU2013337264B2
(en)
|
2012-11-05 |
2018-03-08 |
Foundation Medicine, Inc. |
Novel fusion molecules and uses thereof
|
|
HK1215210A1
(zh)
|
2012-11-07 |
2016-08-19 |
Teva Pharmaceutical Industries Ltd. |
拉喹莫德胺盐
|
|
AU2014207342C1
(en)
|
2013-01-18 |
2019-04-04 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
|
EP2981621B1
(en)
|
2013-04-05 |
2019-05-22 |
Life Technologies Corporation |
Gene fusions
|
|
GB201307577D0
(en)
|
2013-04-26 |
2013-06-12 |
Astex Therapeutics Ltd |
New compounds
|
|
WO2014193229A2
(en)
|
2013-05-27 |
2014-12-04 |
Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis |
Novel translocations in lung cancer
|
|
US20160143911A1
(en)
|
2013-06-14 |
2016-05-26 |
Synthon B.V. |
Stable and water soluble pharmaceutical compositions comprising pemetrexed
|
|
US20160129030A1
(en)
|
2013-06-14 |
2016-05-12 |
The Brigham And Women's Hospital, Inc. |
Treatment of mtor hyperactive related diseases and disorders
|
|
EP3019628A4
(en)
|
2013-07-12 |
2017-05-10 |
The Regents Of The University Of Michigan |
Recurrent gene fusions in cancer
|
|
HK1226058A1
(zh)
|
2013-08-02 |
2017-09-22 |
亚尼塔公司 |
单独地或与其它试剂联合地使用axl/cmet抑制剂治疗多种癌症的方法
|
|
US9221804B2
(en)
|
2013-10-15 |
2015-12-29 |
Janssen Pharmaceutica Nv |
Secondary alcohol quinolinyl modulators of RORγt
|
|
JP6980385B2
(ja)
|
2014-03-26 |
2021-12-15 |
アステックス、セラピューティックス、リミテッドAstex Therapeutics Limited |
Ｆｇｆｒ阻害剤とｉｇｆ１ｒ阻害剤の組合せ
|
|
JO3512B1
(ar)
|
2014-03-26 |
2020-07-05 |
Astex Therapeutics Ltd |
مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
|
|
MA55696A
(fr)
|
2014-03-26 |
2022-02-23 |
Astex Therapeutics Ltd |
Combinaisons
|
|
MX392774B
(es)
|
2014-09-26 |
2025-03-24 |
Janssen Pharmaceutica Nv |
Uso de paneles de genes mutantes de fgfr en la identificacion de pacientes con cancer que responderán al tratamiento con un inhibidor fgfr
|
|
JOP20200201A1
(ar)
|
2015-02-10 |
2017-06-16 |
Astex Therapeutics Ltd |
تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
|
|
AU2016219917B2
(en)
|
2015-02-19 |
2021-12-16 |
Fusion Pharmaceuticals Inc. |
Methods, compositions, and kits for treatment of cancer
|
|
US10478494B2
(en)
|
2015-04-03 |
2019-11-19 |
Astex Therapeutics Ltd |
FGFR/PD-1 combination therapy for the treatment of cancer
|
|
CN105030777B
(zh)
|
2015-07-14 |
2017-07-21 |
中国人民解放军第三军医大学第三附属医院 |
增强alk‑tki疗效、延缓其耐药的复合物及其制剂
|
|
CN105147687A
(zh)
|
2015-09-28 |
2015-12-16 |
青岛华之草医药科技有限公司 |
一种治疗白血病的药物达沙替尼组合物胶囊
|
|
JOP20190280A1
(ar)
|
2017-06-02 |
2019-12-02 |
Janssen Pharmaceutica Nv |
مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية
|